Abstract 4317
Background
Adenocarcinoma of esophagogastric junction (AEG) is a special type of malignant tumor which occurs in the upper gastrointestinal tract. However, AEG is different from esophageal or gastric cancer. Its biological behavior is complicated and prognosis is poor. Even after radical resection, the overall 5-year survival rate is still very low. An in-depth analysis of the prognostic factors in patients with AEG may indicate a certain direction for clinical treatment and decision-making as well as for improving the prognosis of patients with AEG. Although some researchers have explored the factors influencing the prognosis of AEG, the independent prognostic factors are still unclear, which need to be further studied.
Methods
The clinical data of patients with AEG who underwent surgical treatment in PLA general hospital from January 2009 to January 2013 were collected retrospectively. According to the inclusion and exclusion criteria, a total of 343 patients with AEG were included in the study. Sex, age, basic disease, Siewert classification, tumor size (Diameter), differentiation, vascular cancer thrombus, nerve invasion, T-stage,N stage, pTNM, approach, minimally invasive surgery, resection scope, adjuvant chemotherapy, HER-2 and Ki-67 expression were analyzed comprehensively to study the independent or nonindependent prognostic factors in patients with AEG.
Results
The median follow-up time of the 343 patients with AEG was 50.2 months. The 5-year overall survival rate of the whole group (no IV stage) was 49.2%. Univariate analysis showed that age, basic disease, Siewert classification, tumor size (Diameter), differentiation, vascular cancer thrombus, nerve invasion, T-stage,N stage, pTNM, adjuvant chemotherapy, level of Ki-67 expression was correlated with prognosis (P < 0 05). Multivariate analysis showed that age, tumor size(Diameter), differentiation, pTNM and adjuvant chemotherapy were independent prognostic factors affecting the overall survival of the patients (P < 0 05).
Conclusions
The age, tumor size (Diameter), differentiation degree, pTNM and adjuvant chemotherapy were independent prognostic factors affecting the overall survival rate of patients with AEG (P < 0 05).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wangxinxin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1109 - First Canadian Interim Analysis from the Phase IIIb CompLEEment-1 Ribociclib + Letrozole HR+ HER2- Advanced Breast Cancer Trial
Presenter: Cristiano Ferrario
Session: Poster Display session 2
Resources:
Abstract
4401 - Real-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US
Presenter: Jonathan Kish
Session: Poster Display session 2
Resources:
Abstract
5876 - Palbociclib-Fulvestrant (PALBO-FUL) and Everolimus -Exemestane (EVE-EXE) for Second line Hormonal Treatment (HT) of Metastatic Breast Cancer (MBC) with Lobular Histology: a Propensity Score Matched Analysis of a Multicenter ‘Real-World’ Patients (pts) Series.
Presenter: Armando Orlandi
Session: Poster Display session 2
Resources:
Abstract
3587 - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
Presenter: E Dees
Session: Poster Display session 2
Resources:
Abstract
5696 - Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of ER+ Her2- Metastatic breast cancer (mBC)
Presenter: Sacha Howell
Session: Poster Display session 2
Resources:
Abstract
1475 - Alpelisib (ALP) + Fulvestrant (FUL) in Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2–Negative (HER2–) Advanced Breast Cancer (ABC): Subgroup Analysis by Presence of Visceral Metastasis (VM) in the SOLAR-1 Trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
2549 - Phase 1 Dose Escalation Study of a Selective Androgen Receptor Modulator RAD140 in Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) Breast Cancer (BC)
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3787 - A Phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours
Presenter: Binghe Xu
Session: Poster Display session 2
Resources:
Abstract
4835 - Phase-I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
Presenter: Huiping Li
Session: Poster Display session 2
Resources:
Abstract
5083 - Phase 2 study of DHP107 (Liporaxel®, oral paclitaxel) in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)
Presenter: Jin-Hee Ahn
Session: Poster Display session 2
Resources:
Abstract